This project is aimed at delineating the mechanisms by which stimulation of immune cells results in inactivation of the IkappaB-alpha inhibitor and subsequent activation of the NF-kappaB transcription factor. NF-kappaB is critical for the inducible expression of many genes whose encoded functions are required to counteract pathogens or stress. In addition, NF-kappaB regulates the expression of several viruses, including the human immunodeficiency virus (HIV). Therefore, blocking the activation of NF-kappaB could aid in the treatment of many inflammatory diseases and may also prevent the spread of HIV. An understanding of the mechanism(s) of activation of this transcription factor and the identification of the molecular components involved will provide potential targets for anti-inflammatory and anti-viral therapies. We have previously demonstrated that signal-induced activation of the NF-kappaB transcription factor involves rapid site-specific phosphorylation followed by proteolytic degradation of its cytoplasmic inhibitor IkappaB-alpha. Degradation is carried out by proteasomes in a ubiquitin-dependent fashion. We have determined that the inhibitor becomes ubiquitinated on specific lysines as a consequence of induced phosphorylation; the ubiquitinated species is then degraded by proteasomes. The phosphorylation and ubiquitination sites are located near the N-termius of IkappaB-alpha. Efficient degradation also requires PEST sequences located near the C-terminus. We demonstrate that the short N- and C-terminal domains of IkappaB-alpha are not only necessary but also sufficient to confer an inducible degradation phenotype. Attachment of these two domains to a completely unrelated protein caused signal-induced degradation of the chimeric protein. This research will aid in the identification of the molecular components which target the phosphorylated inhibitor for proteasomal degradation and the kinases which phosphorylate it in response to appropriate stimuli.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000723-02
Application #
2566897
Study Section
Special Emphasis Panel (LIR)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Claudio, Estefania; Saret, Sun; Wang, Hongshan et al. (2009) Cell-autonomous role for NF-kappa B in immature bone marrow B cells. J Immunol 182:3406-13
Claudio, Estefania; Sønder, Søren Ulrik; Saret, Sun et al. (2009) The adaptor protein CIKS/Act1 is essential for IL-25-mediated allergic airway inflammation. J Immunol 182:1617-30
Zhang, Xiaoren; Wang, Hongshan; Claudio, Estefania et al. (2007) A role for the IkappaB family member Bcl-3 in the control of central immunologic tolerance. Immunity 27:438-52
Claudio, E; Brown, K; Siebenlist, U (2006) NF-kappaB guides the survival and differentiation of developing lymphocytes. Cell Death Differ 13:697-701
Close, Pierre; Hawkes, Nicola; Cornez, Isabelle et al. (2006) Transcription impairment and cell migration defects in elongator-depleted cells: implication for familial dysautonomia. Mol Cell 22:521-31
Wieland, Gerhard D; Nehmann, Nina; Muller, Doreen et al. (2005) Early growth response proteins EGR-4 and EGR-3 interact with immune inflammatory mediators NF-kappaB p50 and p65. J Cell Sci 118:3203-12
Siebenlist, Ulrich; Brown, Keith; Claudio, Estefania (2005) Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 5:435-45
Wessells, Jennifer; Baer, Mark; Young, Howard A et al. (2004) BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem 279:49995-50003
Viatour, Patrick; Dejardin, Emmanuel; Warnier, Michael et al. (2004) GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell 16:35-45
Xing, Lianping; Carlson, Louise; Story, Beryl et al. (2003) Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J Bone Miner Res 18:260-9

Showing the most recent 10 out of 22 publications